GeneDx (WGS) 10-Q2024 Q2 Quarterly report

Filed: 30 Jul 24, 4:19pm

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. junior Avg

New words: aforementioned, ATM, Conn, Cosmetic, Cowen, enrollment, instructed, light, mediation, principle, purportedly, Scinto, stay, stipulation, TD, thousand, USA

Removed: arrangement, assistance, bill, calculated, cancer, children, classification, client, criteria, designated, exit, experienced, fee, goodwill, hereditary, implementing, meet, model, modification, month, oversight, pandemic, pricing, relating, repay, reputation, satisfy, substantial, variation

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

Associated WGS transcripts

WGS similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.2

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of GeneDx Holdings Corp. (the “registrant”) on Form 10-Q for the quarterly period ended June 30, 2024, as filed with the Securities and Exchange Commission (the “Report”), I, Kevin Feeley, Chief Financial Officer of the registrant, certify, pursuant to 18 U.S.C. §1350, as added by §906 of the Sarbanes-Oxley Act of 2002, that:

1.The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

2.To my knowledge, the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the registrant.


Date: July 30, 2024	By:	/s/ Kevin Feeley
		Kevin Feeley
		Chief Financial Officer (Principal Financial Officer)

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.